Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.
Goineau A, Campion L, d'Aillières B, Vié B, Ghesquière A, Béra G, Jaffres D, de Laroche G, Magné N, Artignan X, Chamois J, Bergerot P, Martin E, Créhange G, Deniaud-Alexandre E, Buthaud X, Belkacémi Y, Doré M, de Decker L, Supiot S. Goineau A, et al. Among authors: bera g. PLoS One. 2018 Apr 9;13(4):e0194173. doi: 10.1371/journal.pone.0194173. eCollection 2018. PLoS One. 2018. PMID: 29630602 Free PMC article.
Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?
Goineau A, Campion L, Commer JM, Vié B, Ghesquière A, Béra G, Jaffres D, Magné N, Artignan X, Chamois J, Bergerot P, Créhange G, Deniaud-Alexandre E, Buthaud X, Belkacémi Y, Doré M, De Decker L, Supiot S. Goineau A, et al. Among authors: bera g. Cancers (Basel). 2020 Mar 9;12(3):635. doi: 10.3390/cancers12030635. Cancers (Basel). 2020. PMID: 32182949 Free PMC article.
Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate fractionated irradiation trial - PROFIT.
Zhou K, Renouf M, Perrocheau G, Magné N, Latorzeff I, Pommier P, Créhange G, Paumier A, Bera G, Martin J, Catton C, Bellanger M, Supiot S. Zhou K, et al. Among authors: bera g. Radiother Oncol. 2022 Aug;173:306-312. doi: 10.1016/j.radonc.2022.06.014. Epub 2022 Jun 27. Radiother Oncol. 2022. PMID: 35772576 Free article. Clinical Trial.
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.
Rogé M, Pointreau Y, Sargos P, Meyer E, Schick U, Hasbini A, Rio E, Bera G, Ruffier A, Quivrin M, Chasseray M, Latorzeff I, Martin E, Guimas V, Pommier P, Leroy T, Ronchin P, Lepinoy A, Grand A, Cartier L, Didas O, Denis F, Libois V, Blanc-Lapierre A, Supiot S. Rogé M, et al. Among authors: bera g. Clin Transl Radiat Oncol. 2023 Mar 8;40:100613. doi: 10.1016/j.ctro.2023.100613. eCollection 2023 May. Clin Transl Radiat Oncol. 2023. PMID: 36968576 Free PMC article.
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Zubel A, Zanna C, Brienza S, Crompton P, Rouits E, Gollmer K, Szyldergemajn S, Bourhis J. Sun XS, et al. Among authors: bera g. Lancet Oncol. 2020 Sep;21(9):1173-1187. doi: 10.1016/S1470-2045(20)30327-2. Epub 2020 Aug 3. Lancet Oncol. 2020. PMID: 32758455 Clinical Trial.
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Tao Y, Sun XS, Pointreau Y, Le Tourneau C, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Calderon B, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Damstrup L, Crompton P, Ennaji A, Gollmer K, Nauwelaerts H, Bourhis J. Tao Y, et al. Among authors: bera g. Eur J Cancer. 2023 Apr;183:24-37. doi: 10.1016/j.ejca.2022.12.015. Epub 2023 Jan 9. Eur J Cancer. 2023. PMID: 36796234 Free article. Clinical Trial.
Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
Boegemann M, Khaksar S, Bera G, Birtle A, Dopchie C, Dourthe LM, Everaert E, Hatzinger M, Hercher D, Hilgers W, Matus G, Alvarez LG, Antoni L, Lukac M, Pissart G, Robinson P, Elliott T. Boegemann M, et al. Among authors: bera g. BMC Cancer. 2019 Jan 14;19(1):60. doi: 10.1186/s12885-019-5280-6. BMC Cancer. 2019. PMID: 30642291 Free PMC article.
[Help for delineation: what kind of tools?].
Pointreau Y, Bera G, Barillot I. Pointreau Y, et al. Among authors: bera g. Cancer Radiother. 2009 Oct;13(6-7):600-5. doi: 10.1016/j.canrad.2009.06.026. Epub 2009 Sep 18. Cancer Radiother. 2009. PMID: 19766526 French.
68 results